Pacific Biosciences (PacBio)
Pacific Biosciences (PacBio) is a foundational life science technology company recognized as one of the two dominant global producers of “true” long-read sequencing technologies. The company designs, develops, and manufactures sequencing systems based on its proprietary Single-Molecule Real-Time (SMRT) sequencing, which has advanced into the highly accurate HiFi long-read sequencing platform. PacBio’s technology is crucial for applications that require comprehensive genome assembly and the resolution of complex genomic regions, providing reads that can extend for thousands of base pairs. The cornerstone of its product line is the Revio long-read sequencing system, introduced to enable customers to dramatically scale their use of HiFi sequencing for high-throughput applications. PacBio’s SMRT sequencing delivers high single-molecule accuracy, often exceeding 90% quality (Q30+), which provides critical alignment accuracy for researchers. Serving pharmaceutical, biotechnology, academic, and governmental sectors, PacBio continually innovates; for example, the new SPRQ chemistry optimizes the Revio system by reducing necessary DNA input four-fold and increasing data output by 33%. By delivering scalable, high-accuracy long-read platforms, PacBio enables breakthroughs in genomics and transcriptomics, catering to the growing demand for highly resolved genetic information.\
Latest Market Research Report on Long Read Sequencing Download PDF Brochure Now
Oxford Nanopore Technologies (ONT)
Oxford Nanopore Technologies plc. is a prominent UK-based biotechnology firm specializing in disruptive nanopore-based sensing technology for molecular analysis, making it the other major producer of “true” long-read sequencing alongside PacBio. The company operates globally through its Life Science Research Tools segment, offering sequencing systems known for their unique ability to generate extremely long reads, often extending into tens of thousands of base pairs. Unlike traditional methods, nanopore sequencing directly reads the sequence from a single DNA or RNA strand as it passes through a protein nanopore, eliminating the need for amplification. The primary advantages of ONT technology include high sequencing timeliness and relatively lower sequencing costs, as well as the ability to provide results rapidly, often within hours. While historically facing challenges with accuracy, the technology is continually improving and is highly valued for its speed and read length. ONT utilizes strategic pricing for its flow cells and consumables, aiming to make its technology accessible across clinical, academic, and research populations worldwide. The company is actively engaged in large-scale personalized medicine initiatives, such as the one in the United Arab Emirates, demonstrating its commitment to advancing genomic research and diagnostics on a massive scale.\
Illumina, Inc.
Illumina, Inc. is globally recognized as the dominant force in the genomics market, particularly in Next-Generation Sequencing (NGS) technology. While its core platforms, like the NovaSeq and HiSeq series, traditionally utilized short-read sequencing by synthesis (SBS) chemistry, Illumina has made strategic moves to address the burgeoning demand for long-read sequencing. In response to competitor advancements, Illumina debuted its own long-read capabilities through a synthetic approach. This strategy involves the Illumina Complete Long Read technology, with products like the Illumina Complete Long Read Prep, Human, designed to be compatible with its vast installed base of NovaSeq systems. The synthetic long-read approach, notably codenamed ‘Infinity,’ is engineered to deliver contiguous data up to 10Kb in length, aiming to resolve the complex “edge cases” of the human genome. This synthetic method is optimized for throughput, requiring up to 90% less DNA input than legacy long-read technologies, and can be fully automated. Illumina’s goal is not necessarily to replace true long-read providers but rather to capture the majority of long-read use cases by leveraging the accuracy, cost-efficiency, and massive scale inherent in their established SBS chemistry, reinforcing their commanding position across all segments of genomic analysis.\
Latest Market Research Report on Long Read Sequencing Download PDF Brochure Now